Back to top
more

SESEN BIO, INC. (SESN)

(Delayed Data from NSDQ)

$1.30 USD

1.30
2,172,114

+0.07 (5.69%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.30 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Brokerage Reports

0 items in cart

Carisma Therapeutics Inc. [SESN]

Reports for Purchase

Showing records 1 - 20 ( 24 total )

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

08/19/2022

Company Report

Pages: 6

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/09/2021

Company Report

Pages: 6

Progress on CMC for BLA Resubmission; Awaiting Clarity on Clinical Front; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for SESN

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

08/16/2021

Company Report

Pages: 6

Vicineum Received CRL; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

08/10/2021

Company Report

Pages: 6

All Eyes on Vicineum PDUFA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

05/11/2021

Company Report

Pages: 4

Awaiting the FDA’s Decision on Vicineum; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

03/16/2021

Company Report

Pages: 6

Catalyst-Rich 2021 Ahead; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

02/17/2021

Company Report

Pages: 6

Vicineum Granted Priority Review; Higher $8PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

11/10/2020

Company Report

Pages: 7

Vicineum BLA Submission in Q4 With MAA Planned in 2021; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

08/11/2020

Company Report

Pages: 6

Steady Progress Towards Vicineum BLA Completion; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/03/2020

Daily Note

Pages: 3

First OUS Deal Inked for Vicineum; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

05/12/2020

Company Report

Pages: 6

Vicinium BLA on Track; EU Submission Expected in 2021; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

03/17/2020

Company Report

Pages: 6

Vicinium BLA Submission on Target; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

11/13/2019

Company Report

Pages: 7

Vicinium on Track for Potential 2021 Launch; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/12/2019

Company Report

Pages: 7

Vicinium Could Receive US Approval in 2020; Adjusting PT to $2.25 on Dilution; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

06/11/2019

Company Report

Pages: 7

Positive FDA Feedback Paves Way for 4Q19 Filing; Upgrade to Buy with $3.00PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

05/14/2019

Company Report

Pages: 9

Additional Data From Phase 3 Vista Study; Two FDA Meetings Imminent; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

03/05/2019

Company Report

Pages: 9

Additional Results Fail to Improve Vicinium’s Commercial Potential; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

01/04/2019

Company Report

Pages: 8

Preliminary VISTA Results Fail to Impress; Lowering to Neutral With $1.00PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Carisma Therapeutics Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

11/28/2018

Company Report

Pages: 5

Takeaways From Our KOL Dinner on Bladder Cancer; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party